Navigation Links
Hospira Reports Third-Quarter 2012 Results
Date:11/7/2012

>

$214.3

$303.9

(29.5)%

$334.0

$361.3

(7.6)%(Loss) Income from

Operations

$(16.5)

$(85.2)

80.6%

$112.6

$142.4

(20.9)%Diluted Earnings (Loss) per

Share

$0.01

$(0.54)

101.9%

$0.47

$0.66

(28.8)%Statistics (as a % of Net Sales)Gross Profit (Net Sales less

Cost of Products Sold)

21.6%

31.1%33.6%

37.0%(Loss) Income from

Operations

(1.7)%

(8.7)%11.3%

14.6%Results under U.S. GAAP include items as detailed in the schedules attached to this press release.

Net sales for the quarter were $994 million, an increase of 1.8 percent compared to $977 million in the third quarter of 2011. On a constant-currency basis, third-quarter 2012 net sales increased 3.9 percent compared to the third quarter of 2011. Strong U.S. sales of several Specialty Injectable Pharmaceutical (SIP) products, including Precedex™ and the oncolytic oxaliplatin, which was relaunched during the quarter, as well as higher volumes for certain SIP products in the company's Europe, Middle East and Africa (EMEA) region, contributed to the positive performance in the quarter. The strong SIP performance more than offset the impact to supply in 2012 of the company's quality-improvement and remediation initiatives.

Adjusted* income from operations for the third quarter of 2012 was $113 million compared to $142 million in the third quarter of 2011. The majority of the decline reflects the impact of costs associated with higher year-over-year manufacturing expense. On a GAAP basis, the loss from operations for the third quarter of 2012 was $17 million compared to a loss from operations of $85 million in the third quarter of 2011. On a GAAP basis, in addition to the higher year-over-year manufacturing expense, the third quarter of 2012, and to a lesser extent, the third quarter of 2011, included
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  Cryoport, Inc. (NASDAQ: ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, announced today that the Company ... warrants (the "Units") under a registered public offering.  ...
(Date:7/29/2015)... , July 29, 2015  Ortho-Clinical Diagnostics, Inc. ... assays under development. The assays address a range of ... injury and cardiac troponin I. The scientific posters will ... Chemistry Annual Meeting to be held July 26 - ... "Ortho Clinical Diagnostics is emerging stronger than ...
(Date:7/29/2015)... July 29, 2015 The Judicial Panel on ... about whether to centralize Inferior vena cava (IVC) Filter ... manufacturer, Cook Medical, have already been centralized by the ... in patients at risk for a pulmonary embolism. The ... to the lungs. Claims against Bard and Cook involve ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3IVC filter litigation continues; law firm provides free information to IVC filter patients 2
... New results from an observational substudy from TRITON–TIMI ... (AHA) Scientific Sessions annual meeting showed that patients ... bypass graft surgery (CABG) had a reduced overall ... (clopidogrel) (2.3 percent versus 8.7 percent respectively, p=0.016).(1) ...
... Nov. 16, 2010 New results from an ... the American Heart Association (AHA) Scientific Sessions annual ... prior to coronary artery bypass graft surgery (CABG) ... patients treated with Plavix® (clopidogrel) (2.3 percent versus ...
Cached Medicine Technology:Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 2Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 3Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 4Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 5Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 6Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 2Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 3Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 4Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 5Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 6
(Date:7/29/2015)... ... July 29, 2015 , ... This year, the threat of flooding is ... And, where there is water, mold is not far behind. Paul Davis, a leading ... against water and mold damage. Paul Davis is regularly called on to handle these ...
(Date:7/29/2015)... WI (PRWEB) , ... July 29, 2015 , ... ... Scott Campbell Agency has once again teamed up with Stillwaters Cancer Support Services ... and their families. Stillwaters provides individual and family counseling, support groups, workshops and ...
(Date:7/29/2015)... ... July 29, 2015 , ... Today marks a significant achievement in bringing ... growth companies and is led by a group of experienced investors, has tapped into ... with their dollars to be a part of the fund. The Sofia Fund ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... Farmer, airing fall of 2015 on RFD-TV. , Fastline is dedicated to quality ... about Fastline.com, which contains the largest and freshest searchable agriculture equipment database in ...
(Date:7/29/2015)... ... July 29, 2015 , ... It is unique for a health ... tremendous model of care. One that is very hands on and resident oriented, and ... Monarch Landing. “She’s bringing great passion and energy, as well as a strong commitment ...
Breaking Medicine News(10 mins):Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 2Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 3Health News:Sofia Fund Surpasses Investor Goals 2Health News:Fastline Publications to Partner with American Farmer in Upcoming Episode Airing on RFD-TV 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 3
... retailer,s $4 drug program the largest of its kind, ... its,commitment to improving the health and wellness of its ... this,Thursday, November 8, 2007, the company will expand its ... of more than 400. The program makes commonly ...
... to medication regimen, study finds , WEDNESDAY, Nov. 7 ... with high blood pressure stick to the drug regimens ... , Older black Americans tend to have poorer anti-hypertensive ... even though adherence helps reduce hypertension-related health problems and ...
... SAN DIEGO, Nov. 7 CryoCor, Inc. (Nasdaq:,CRYO), a ... announced today that it will release its financial results ... 13, 2007 after,the close of the U.S. financial markets. ... conference call at 5:00 p.m. ET /,2:00 p.m. PT ...
... CLEVELAND, Nov. 7 JumpStart Inc., Northeast ... commitment of,$350,000 in Aria Analytics, Inc. Aria ... that measures the physical and chemical,attributes of ... acoustically,probing the sample during evaporation. (Logo: ...
... a mouse feels, thanks to a new technique which uses ... the brain which regulates appetite. , Researchers hope the ... greater understanding of why certain people become obese when others ... new study, led by researchers from Imperial College London, is ...
... on multiple fronts, researchers say , , WEDNESDAY, Nov. 7 ... VN/14-1 proved effective in treating human prostate cancer, say ... The five-week study found that daily injections of VN/14-1 ... in up to a 50 percent reduction in tumor ...
Cached Medicine News:Health News:Giant Eagle Expands Popular Generic Prescription Program and Now Offers '400 for $4' 2Health News:Spirituality Helps Older Black Women Beat Hypertension 2Health News:CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results 2Health News:Aria Analytics Receives JumpStart Investment 2Health News:Aria Analytics Receives JumpStart Investment 3Health News:Obesity research boosted by watching hunger in the brain 2Health News:Experimental Drug Fights Prostate Cancer 2
... Sorvall DiscoveryTMM150 SE Micro-ultra centrifuge continues to ... sample processing, now with 1,048,000 x g ... rotor. DiscoveryTMM150SE processes sample sizes from ... small floor footprint, brushless direct drive, very ...
... highest g-force ever. But optimal productivity in ... MAX combines maximum force, capacity, and ease ... worlds apart from any other system. With ... efficiency, Optima takes productivity to the MAX. ...
... Efficiency, versatility, and environmental ... the Optima LE-80 K Ultracentrifuge ... Coulters innovative Optima centrifugation technology, ... to cost effectively provide advanced ...
... generating 694,000 x g at ... Beckman Coulter's Optima L-90K Ultracentrifuge ... separations in less time. This ... a broad range of superb ...
Medicine Products: